|
Variable
|
Evaluation
|
Hazard ratio (95% confidence interval)
|
P value
|
|---|
|
Tumour size
|
T1 (≤ 2 mm)
|
1
| |
| |
T2 (2 < T ≤ 5 mm)
|
1.45 (0.40 to 5.21)
|
0.567
|
| |
T3 (>5 mm)
|
3.57 (0.88 to 14.4)
|
0.073
|
|
Lymph node stage
|
Negative
|
1
| |
| |
1 to 3 lymph nodes
|
0.47 (0.10 to 2.16)
|
0.338
|
| |
>3 lymph nodes
|
2.49 (1.02 to 6.03)
|
0.044
|
|
Tumour grade
|
Grade I
|
a
| |
| |
Grade II
|
1
| |
| |
Grade III
|
2.85 (1.05 to 7.57)
|
0.040
|
|
HER-2/neu expression
|
HER-2/neu-negative
|
1
| |
| |
HER-2/neu-positive
|
2.04 (0.90 to 4.61)
|
0.086
|
|
FOXA1 expression
|
FOXA1-positive
|
1
| |
| |
FOXA1-negative
|
3.61 (0.83 to 15.60)
|
0.086
|
|
GATA-3 expression
|
GATA-3-positive
|
1
| |
| |
GATA-3-negative
|
1.53 (0.44 to 5.28)
|
0.495
|
- FOXA-1, forkhead box A1; GATA-3, GATA binding protein 3; HER-2, human epidermal growth factor receptor 2. aThere were no oestrogen-receptor-negative cases classified as grade I among the patients with available follow-up information.
